Health
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J., February 17, 2026--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/24c605839825700064bf4f7f09e7424f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_HP_EDS33D0hp8GEn66Pew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/24c605839825700064bf4f7f09e7424f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/tpEbIsH1O3NDjSLFELI9QQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/24c605839825700064bf4f7f09e7424f","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Iberdomide has the potential to be the first approved CELMoD agent","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"The U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of August 17, 2026","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., February 17, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab + dexamethasone - IberDd) in patients with relapsed or refractory multiple myeloma (RRMM). Iberdomide is part of an investigational, new class of medicines called cereblon E3 ligase modulator (CELMoD) agents. The FDA has granted a Prescription Drug User Fee Act (PDUFA) date of August 17, 2026 for this indication.","length":568,"tagName":"p"},{"type":"text","content":""The FDA’s acceptance of this application is a testament to the potential of iberdomide, in combination with anti-CD38 monoclonal antibodies, as a novel, potent, oral treatment option, with a manageable safety profile, for patients with multiple myeloma," said Cristian Massacesi, executive vice president and chief medical officer, Bristol Myers Squibb. "Furthermore, our filing for iberdomide based on the MRD endpoint, underscores our commitment to pioneering new ways of advancing life-saving therapies for patients living with cancer."","length":560,"tagName":"p"},{"type":"text","content":"The filing was based on results f...